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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The molecular 
mechanisms underlying hepatocarcinogenesis are still poorly understood. Genetically modified mice are powerful 
tools to further investigate the mechanisms of HCC development. However, this approach is limited due to the lack of 
non-invasive detection methods in small rodents. The aim of this study was to establish a protocol for the non-invasive 
analysis of hepatocarcinogenesis in transgenic mice using a clinical 1.5 Tesla Magnetic Resonance Imaging scanner.
Results: As a model system we used hepatocyte-specific c-myc transgenic mice developing hepatocellular carcinoma 
at the age of 12-15 months. The scans of the murine livers included axial T2-weighted turbo-spin echo (TSE) images, 
axial T1-weighted and contrast enhanced T1-weighted gradient echo (fast field echo, FFE) and sagittal true Fast 
Imaging with Steady state Precession (true-FISP) images. Application of contrast agent was performed via tail vein-
catheter and confirmed by evaluation of the altered longitudinal relaxation T1 time before and after application. 
Through technical adaptation and optimization we could detect murine liver lesions with a minimum diameter of 
approximately 2 mm and provided histopathological evidence that these MR findings correspond to hepatocellular 
carcinoma. Tumor growth was repeatedly measured using sequential MRI with intervals of 5 weeks and subsequent 
volumetric analysis facilitating direct comparison of tumor progression between individual animals. We finally 
demonstrated that our protocol is also applicable in the widely- used chemical model of N-nitrosodiethylamine-
induced hepatocarcinogenesis.
Conclusion: Our protocol allows the non-invasive, early detection of HCC and the subsequent continuous monitoring 
of liver tumorgenesis in transgenic mice thereby facilitating future investigations of transgenic tumor mouse models of 
the liver.
Background
Hepatocellular carcinomas (HCC) represent one of the
most common cancers with growing incidence in several
regions around the world. The major cause for HCC
development is chronic liver disease. Although the exact
molecular mechanism leading to HCC progression is still
poorly understood, it is well accepted that chronic liver
damage is associated with continuous cycles of apoptosis
and/or necrosis followed by compensatory proliferation
of hepatocytes. This triggers liver fibrosis and cirrhosis
but also results in the accumulation of mutations and
transformed hepatocytes due to excessive DNA replica-
tion and increased mitosis during liver regeneration.
Accordingly, a number of genes involved in cell cycle pro-
gression and apoptosis including E2F [1,2], c-myc [3] or
the pro-apoptotic protease caspase-8 [4] were shown to
be deregulated in HCC and the number of identified
genes affecting hepatocarcinogenesis is permanently
increasing.
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Page 2 of 13During the last decades, the treatment options for
patients with advanced HCC have been very limited due
to a lack of effective conventional systemic chemother-
apy. Promising progress was reported recently by the use
of the multi-kinase inhibitor Sorafenib in patients with
advanced hepatocellular carcinoma leading to signifi-
cantly increased overall survival [5]. Consequently,
Sorafenib treatment is now the new standard of care for
those patients. However, the benefit from Sorafenib treat-
ment concerning overall survival is rather moderate.
Therefore, there is still the need for more effective thera-
pies in HCC treatment [6].
In order to define new and better therapeutical targets,
strong efforts have been made during the last years to
better understand the molecular mechanisms of hepato-
carcinogenesis. One promising approach is the analysis of
transgenic - or knockout mice specifically targeting
tumor promoters or tumor suppressors such as c-myc,
p53, p21 and others [7-11]. Indeed, earlier analysis of
these animals gave a deep insight into the mechanisms of
tumor development in the liver and other organs
[8,12,13]. However, recent approaches to measure and
compare the tumor incidence and tumor progression
between different transgenic mouse lines are still prob-
lematic due to a lack of appropriate techniques and detec-
tion methods to monitor tumor initiation and tumor
growth in vivo. Thus, current reports still rely on a huge
amount of animals per group which have to be sacrificed
at distinct time points for the measurement of tumor size.
Subsequently, methods for the continuous monitoring of
liver tumor growth in individual transgenic mice need to
be developed.
Magnetic Resonance Imaging (MRI) has been used in
many clinical, biomedical, chemical and engineering
applications. In clinical practice, MRI is used to visualize
the internal structure of organs and tissue of the body
with a special focus on neurological (brain), cardiovascu-
lar and oncological imaging including HCC in particular
[14].
In comparison to ultrasound and Computed tomogra-
phy (CT), MRI has proven to be more reliable when focal
liver lesions have to be detected and characterized
[15,16]. This greater potential is based on a superior
amount of diagnostic information by the assessment of
T1- and T2-weighted sequences and the possibility of
multiple sequences after injection of contrast media.
Application of contrast media leads to its accumulation
within the lesions early after injection due to the higher
distribution volume and causes a decrease of the T1
relaxation time. Furthermore, an increase in focal liver
lesion detection has been reported with the introduction
of the liver-specific contrast agent gadoxetic acid diso-
dium [17]. This contrast medium is taken up by intact
hepatocytes in the later phases after injection and washed
out from hepatocellular carcinoma.
CT can also be used for the detection and characterisa-
tion of focal liver lesions. However, this modality exposes
small rodents to relatively high doses of radiation there-
fore potentially influencing hepatocarcinogenesis. Ultra-
sound on the other hand may not allow objective imaging
of all anatomical regions in mice. Based on these consid-
erations, MRI was preferred for longitudinal follow up
imaging in rodents. MRI is not associated with radiation
exposure and can be repeatedly used for imaging of small
animals without any long term effects or alteration of the
course of the disease.
Therefore the aim of this study was to establish a proto-
col for the non-invasive and reliable detection of murine
HCC - induction and progression using MRI techniques.
As specialized MR scanner for small rodents with higher
magnetic field strength are expensive and not available in
most clinical research centres, an additional requirement
for this protocol was the applicability for regular clinical
1.5 Tesla MR-scanning systems.
Results
Establishment of a standard protocol for the MRI analysis of 
transgenic mice
After correct positioning of the mouse in the MRI scan-
ner in the supine position, a short localizer sequence (see
Table 1, row 1) was performed in order to assess effec-
tively the following sequences. Based on these images,
axial T1-weighted and T2-weighted scans were planned
(see Table 1, row 2 and 3).
For better diagnosis and localization of potential liver
lesions, a sagittal 3D true-FISP sequence and an axial
Look-Locker sequence (see Table 1, row 4 and 5) were
performed additionally. The latter one was used to prove
successful administration of contrast agent. The acquisi-
tion of all pre-contrast scans lasted 13 minutes. After all
pre-contrast scans had been performed the contrast
medium was administered for optimized lesion detection
and the Look-Locker sequences as well as the T1-
weighted gradient echo sequences were repeated for
analysis.
The scan parameters were optimized, using wildtype
(WT) mice (Figure 1A) by modifying TR/TE values, flip
angle and slice thickness (compare Table 1) until the
internal liver architecture including the liver vascular sys-
tem and the gall bladder could clearly be distinguished. In
T1-weighted sequences, fat and fat containing tissue (e.g.
bone marrow) appear bright (hyperintense) and the
structure of organs is clearly detectable. Therefore, in
clinical use, T1-scans serve to demonstrate anatomical
organ structure. Figure 1B shows a T1-weighted scan of
an un-enhanced murine liver, which is characterized by
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chyma indicating healthy liver tissue. For better localiza-
tion of the liver and potential pathological lesions, we
further performed sagittal true-FISP imaging (Figure 1C),
showing the complete liver within the whole body con-
text. The optimized standard protocol for MRI in mice
included the use of contrast enhancing sequences. There-
fore, a T1-weighted scan was acquired before and after
administration of contrast agent allowing better determi-
nation of pathological alterations within the tissue. For
Table 1: MRI parameters
No. Sequence 
type
Plane TR/TE Thickness 
(mm)
FOV (mm) Flip angle 
(degrees)
Time
1 FI2 MST axial, 
sagittal, 
parallel
9.40/4.20 3.00 110.0 30 1:28.5
2 T2TSE axial 1800/110 2.00 60.0 90 2:34.8
3 T1WFFE axial 253/6.7 2.00 45.0 80 4:58.3
4 Look-
Locker
axial 9.7/4.5 3.00 70.0 15 2:48.0
5 true-FISP sagittal 9.40/4.20 1.50 80.0 30 1:03.2
The repetition time (TR) parameter determines the user defined repetition time in spin echo sequences while the time of echo (TE) 
determines the excitation pulse (90°) of the same slice. FOV (Field of view) specifies the area to be imaged. Flip determines the angle by which 
the magnetization vector is rotated around to an axis perpendicular to the main magnetic field during the radio frequency excitation pulse. 
It can be adjusted for an optimum contrast and/or signal-to-noise ratio.
Figure 1 MR images of a healthy liver from a 35 weeks old WT mouse using a 1.5 Tesla scanner. (A) Healthy liver of a 35 weeks old mouse after 
resection. (B) T1-weighted gradient echo image of a healthy mouse liver. (C) Sagittal true-FISP images of the same mouse. The location of the liver is 
highlighted in red. (D) Distinct images of T1-weighted sequence after application of contrast agent. Structures of different organs are clearly visible 
and highlighted (red arrow: right kidney; green arrow: heart). (E) Distinct images of healthy mouse liver using T2-weighted sequence, specifically sen-
sitive to water content. Blue arrow pointing to mesh-work of blood vessels. Orientation labeling: R: right; L: left; H: head; A: anterior; P: posterior; F: foot.
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Page 4 of 13this purpose, gadoxetic acid disodium was used, which is
a gadolinium-based hepatocyte-specific contrast agent
for T1-weighted liver imaging. Uptake of gadoxetic acid
disodium led to marked signal enhancement in hepatic
tissue resulting in a brighter appearance of the liver (com-
pare Figure 1D, medium panel and Figure 1B). Moreover,
application of T1-weighted scans allowed a precise dis-
play of the anatomical organ structure in mice (Figure
1D) clearly showing defined structure of right kidney,
liver and beginning section of the murine heart.
In T2-weighted spin echo sequences water- and fluid-
containing tissues (e.g. vessels) are strongly demarcated
from the surrounding tissue and have a bright appear-
ance. T2-weighted imaging of a healthy murine liver
clearly demonstrated the dark healthy liver parenchyma
crossed by a hyperintense mesh-work of connective
blood vessels (Figure 1E).
In summary, these initial experiments demonstrated
that the optimized parameters shown in Tab. 1 allow the
precise imaging of a murine liver in axial and sagittal ori-
entation.
MRI of tumor-susceptible c-myc transgenic mice
Hepatocyte-specific, c-myc transgenic mice (alb-myctg)
are a well established animal model for hepatocarcino-
genesis. These animals develop slow growing liver tumors
similar to a group of human HCCs with better prognosis
and survival [3]. As a starting point of our study we deter-
mined the age-dependent tumor incidence of alb-myctg
mice showing less than 40% of HCCs in 45 weeks old ani-
mals, whereas 80% of the 65 weeks old mice had a mini-
mum of one liver tumor (Figure 2) which is comparable to
earlier findings [18].
To proof whether our optimized MRI parameters (com-
pare Tab. 1) were sufficient to detect HCCs, we started
our analysis with a group of n = 24 alb-myctg mice at the
age of 65 weeks and a predicted tumor probability of 80%.
Following contrast enhanced T1-weighted imaging and
comparison with respective T2-weighted scans, in 15 out
of 18 animals pathologically conspicuous areas were
detected in sections which could clearly be allocated to
the liver. A representative example is shown in Figure 3A-
D. The T1-weighted contrast-enhanced sequence (Figure
3A) indicates extensive tumor invasion throughout the
entire left hepatic parenchyma. The hypervascular nature
and the inhomogeneous internal structure of the tumor
are important criteria in the differential diagnosis of this
liver compared to the even texture of a healthy animal
(compare Figure 1D). Furthermore, sagittal 3D true-FISP
sequences displayed a strong deformation of the liver
(Figure 3B) compared to wildtype mice (see Figure 1C). A
representative image of a T2-weighted sequence showed
the dark liver parenchyma together with an isointense
tumor node of the left hepatic lobe (Figure 3C). Final con-
firmation of the diagnosed HCC was obtained upon sur-
gical removal and macroscopical analysis of the liver as
depicted in Figure 3D. These initial findings indicate
clearly that the developed MRI protocol is applicable to
display tumor formation in the murine liver.
Hypointense MR signals in livers of c-myc transgenic mice 
correspond to highly tumorigenic tissue sections with 
strong proliferation
Next, we aimed to provide clear evidence that hypoin-
tense signals in murine livers correspond to carcinogenic
lesions by correlating our results with histological and
molecular findings.
65 weeks old animals showing MR signals related to
HCC (Figure 4A) were sacrificed and their livers immedi-
ately perfused with 4% formaldehyde for in situ fixation
of the organ. Remarkably, 100% of these MR-positive ani-
mals showed macroscopically clear signs of strong HCC
development (Figure 4B). Before liver sampling, the ori-
entation of all liver lobes relative to the longitudinal,
transversal and sagittal axis of the animals were marked
and the respective, complete liver embedded in paraffin
used in routine diagnostic procedures.
This approach allowed us to fix the liver in a three-
dimensional orientation corresponding to the original in
vivo orientation. These samples were then sectioned in
the axial orientation thus completely comparable to the
MR plane of T1- and T2-weighted sequences. Of notice,
these crude paraffin sections already showed strong simi-
larity with the MR imaging results as hypointense signals
were completely congruent with striking tissue abnor-
Figure 2 Tumor incidence of hepatocyte-specific c-myc transgen-
ic mice at the age of 45-65 weeks. Tumor incidence in alb-myctg 
mice used in this study. A subset of animals was sacrificed at the age of 
45 weeks (alb-myctg: n = 20), 55 weeks (alb-myctg: n = 10) and 65 weeks 
(alb-myctg: n = 16), respectively. The extracted livers were analyzed for 
macroscopically visible tumor nodes. Tumor-positive mice were de-
fined as animals with a minimum of 1 tumor node with a diameter ≥ 1 
mm.
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Page 5 of 13malities in the paraffin sections (compare Figure 4A and
4C). Hematoxylin/eosin staining of whole liver sections
confirmed that hypointense MR signals correspond to a
pathological liver architecture (Figure 4D) and direct
comparison of MR images and histologies revealed that
the MRI was able to detect internal liver tumor nodes
beginning with diameters of 2 mm (compare 4A and 4D).
Detailed histological analysis of the tumor-transformed
liver tissue revealed characteristics of hepatocellular neo-
plasia with some features of hepatocellular carcinoma
(Figure 4E-F). Histomorphological stigmata for neoplas-
tic growth of hepatocytes were nodular arrangement of
cells variable in size and nuclear configuration, a mac-
rotrabecular pattern of tumor cells, increased mitotic
activity, atypical mitosis, destruction of both portal areas
Figure 3 Detection of advanced HCC in mice. (A) After i.v. injection of the extracellular contrast agent gadoxetic acid disodium, irregular structure 
of tumor becomes obvious in T1-weighted scans and is highlighted in red. The carcinoma is visible as hypointense signal spread over the organ, due 
to lack of accumulation of the contrast medium. The surrounding hepatocytes have taken up the contrast agent, which is then present in the intrac-
ellular space and causes reduction of T1 relaxation time. (B) Sagittal 3D true-FISP clearly shows strong deformation of the liver. Localization of total 
liver including carcinoma is highlighted in red. (C) Imaging of the same tumor in a T2-weighted scan revealed an isointense area covering the left 
hepatic lobe. Red dashed line indicates large tumor. (D) Macroscopic appearance of the respective liver after surgical removal confirms large HCC cov-
ering the left part of the liver of an alb-myctg mouse at 65 weeks of age. White dashed line indicates large tumor. Orientation labeling: R: right; L: left; 
H: head; A: anterior; P: posterior; F: foot.
Freimuth et al. Molecular Cancer 2010, 9:94
http://www.molecular-cancer.com/content/9/1/94
Page 6 of 13
Figure 4 Hypointense MR signals in livers of alb-myctg mice correspond to highly tumorigenic tissue sections with strong proliferation. (A) 
T1-weighted liver MR image of a 65 weeks old male alb-myctg mouse after i.v. application of gadoxetic acid disodium. Sharply demarcated multiple 
hypointense foci become obvious within hepatic lobes due to contrast uptake of surrounding hepatic tissue (indicated by arrows); one lesion (white 
circle) was followed up in subsequent analyses. (B) Macroscopic appearance of explanted liver showing multifocal and sometimes multinodular tumor 
growth characterized by enhanced vascularisation, discoloration, and destruction of liver segments. (C) Paraffin-embedded section of the complete 
mouse liver shown in (B). Please note that these serial sections were performed in the same transversal orientation as performed for the MR imaging 
shown in (A). White circle: macroscopically visible tissue abnormality corresponding to hypointense signal as highlighted in (A). (D) Hematoxylin/eosin 
staining of the liver section shown in (C). White circle highlights one selected neoplastic lesion surrounded by normal liver tissue. Scale bar indicates 
diameter of the lesion (mm). (E) Enlarged view (200× original magnification) of mouse liver section with lesions after staining with hematoxylin/eosin. 
(G) PCNA staining (brown nuclei) of liver tissue as a marker for cell proliferation demonstrates DNA synthesis only in areas identified as HCC and (H) 
close-up view (200× original magnification) of tumorous areas in PCNA staining. Black arrows indicate PCNA positive nuclei; dashed black line sepa-
rates healthy liver tissue from tumor nodule; Orientation labeling: R: right; L: left.
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Page 7 of 13and liver lobules, and, occasionally, starting of vascular
infiltration with thinning of the vascular vessel wall.
PCNA is an essential factor for initiating DNA synthe-
sis and thus an established marker for proliferating cells.
To definitely prove that positive signals identified by MRI
correspond to hyperproliferative, tumorigenic nodules,
whole liver sections were stained for nuclear PCNA
expression. Strong accumulation of PCNA-positive cells
was evident exclusively in areas corresponding to liver
regions with hypointense signals in T1-weighted MR
images (Figure 4G-H) demonstrating that MRI of the
murine liver can specifically detect dysplastic nodules
with strong hepatocyte proliferation.
Monitoring of HCC progression
A further prerequisite for the application of MRI in
murine tumor studies of the liver was the option to moni-
tor tumor growth of HCCs in mice and the respective
comparison of tumor size in different animals. Therefore
periodical MR imaging was performed in a cohort of alb-
myctg animals starting at the age of around 45 weeks. The
animals were monitored every 5 weeks and the tumor
growth of detected HCCs was analyzed by measuring
liver and tumor volume using the off-line workstation.
Tumor measurement was performed on the basis of T1-
weighted contrast-enhanced scans. Figure 5A shows a
representative example of a T1-weighted contrast-
enhanced (left panel) and a T2-weighted sequence (right
panel) of a 47 weeks old alb-myctg mouse with three dis-
tinct tumor nodes. Measurement of the median nodule
revealed a volume of 0.4 cm3 (Figure 5B). Time-depen-
dent monitoring demonstrated that the size of this nod-
ule increased only slightly up to 58 weeks of age followed
by a duplication of tumor size between 58-63 weeks of
age (Figure 5B) which corresponded to an increase of
total liver volume (Figure 5C). These findings demon-
strate that alb-myctg HCCs are slow progressing tumors
as strong tumor progression is restricted to old animals
which is in good agreement with earlier reports [3].
Taken together we demonstrated that the protocol
established in this study in combination with the available
technical equipment allows the measurement and com-
parison of tumor progression among diverse types of
transgenic mice.
Limitations for detection of small liver tumors in transgenic 
mice
The last aim of this study was to determine the smallest
size of nodules in murine livers, which are already detect-
able on 1.5 T MRI scans. Therefore, 33 animals at the age
of 45-57 weeks (tumor incidence of approximately 50%)
were scanned by MRI and checked for hypointense sig-
nals in contrast-enhanced T1-weighted images. Immedi-
ately after MRI the animals were sacrificed and the
respective livers were macroscopically and histologically
analyzed for HCCs. The size and location of the macro-
scopic tumor nodes was measured and correlated to the
MRI findings. Overall, 22 out of 33 animals (66%) with
evidence of hypointense signals in contrast-enhanced T1-
weighted images displayed also tumor nodes with a size
between 2 and 10 mm of diameter.
The data for one representative animal is shown in Fig
6. Liver lesions could be identified only dimly on T1-
weighted scans before contrast-enhancement (Figure 6A)
while on the sagittal 3D true-FISP un-enhanced scan
(Figure 6B) two hyperintense areas are already visible.
However, after application of contrast agent (Figure 6C)
multiple hypointense signal patterns appeared in the scan
of the right hepatic lobe, which were also detectable in
T2-weigthed sequences (Figure 6D). Following resection
and macroscopic analysis of the respective liver lobes, the
size of macroscopic tumor nodules was measured and
correlated to the size of hypointense T1-weighted, con-
trast-enhanced MRI signals (compare Figure 6C and 6E)
by using the off-line workstation. These data revealed
that reliable identification of murine tumor nodes begin-
ning at a size of 2 mm in the liver is possible by 1.5 T MRI.
Of note, out of all animals between 45 and 65 weeks of
age 100% of tumors with ≥ 4 mm of diameter were veri-
fied by MRI, whereas only 70% of tumors with a diameter
≤ 4 mm could be detected with the same settings.
Application of MRI in an alternative, c-myc-independent 
mouse model of HCC development
So far, our experiments were exclusively performed in c-
myc transgenic mice and wildtype controls. In order to
prove that our MR protocol also allows detection of
murine HCC in tumor models with different pathogene-
sis, we decided to use the widely-used, well accepted
model of chemically induced HCC in mice using N-
nitrosodiethylamine (DEN).
The carcinogenic effect of DEN is mediated via its
capability of alkylating DNA structures. In most mouse
strains, a single injection of DEN in juvenile mice at the
age of 14 days leads to multinodular hepatocarcinogene-
sis within 40-50 weeks in 80-100% of the animals [19].
Genetic analyses revealed that this model well reflects
human HCC associated with poor prognosis [3]. We
therefore treated a cohort of WT mice with DEN and
subjected these animals to MRI 45 weeks after tumor
induction. Immediately after imaging the mice were sac-
rificed and subjected to macroscopic and histopathologi-
cal analysis of whole liver and tissue sections,
respectively. Macroscopic analysis of extracted livers con-
firmed the multinodular character of this tumor model
showing an average of 74 (SD ± 8.7) tumor nodes per liver
with a high variation of tumor size ranging from 1-13 mm
in size (median tumor size 2.9 ± 2.4 mm Ø, Figure 7A). In
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Figure 5 Monitoring of HCC progression in c-myctg mice. (A) Periodical measurement of tumor growth in an alb-myctg mouse liver at 47, 52, 58 
and 63 weeks of age in T1-weighted contrast-enhanced and T2-weighted sequences. Red circle: tumor node measured for volumetric statistics. (B) 
Chronological progression of tumor growth within 15 weeks demonstrated on one representative tumor node. Volumetric data was obtained using 
an off-line workstation. (C) Measurement of increasing mouse total liver volume within 15 weeks. Median of three independent measurements is 
shown. Orientation labeling: R: right; L: left.
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Page 9 of 13the sagittal 3D true-FISP sequences multiple tumors were
displayed as clearly defined hyperintense structures with
deformation of the normal liver architecture (Figure 7B).
In T1-weighted imaging without contrast enhancement
(Figure 7C) the sub-group of large tumors could be well
displayed as either hypointense- or isointense structures.
Of notice, also nodule-within-nodule like structures,
which have been suggested as morphologic marker of de-
differentiation [20] could be visualized (compare Figure
7F). However, only very few small sized tumors could be
verified in the un-enhanced T1-weighted scans. Follow-
ing contrast enhanced T1-weighted imaging (Figure 7D),
a significant number of additional tumors could be dis-
played as mostly hypointense structures comparable to
our results in c-myc transgenic mice. In T2-weighted spin
echo sequences the destruction of normal liver morhol-
ogy was clearly visible (Figure 7E). Moreover, T2-
weighted imaging allowed at least the detection of a sub-
group of HCC representing the larger tumor nodes.
The histopathological analysis (Figure 7F-K) confirmed
our findings and identified the hypointense MR struc-
tures as well-differentiated or moderately differentiated
nodular-type hepatocellular carcinomas, respectively.
The latter ones were morphologically characterized by a
more irregular configuration of nuclei and cytoplasm.
In summary, these experiments demonstrated that our
MRI protocol for HCC imaging in mice is not restricted
to c-myc transgenic animals, but also applicable to chem-
ical HCC models with completely different pathogenesis.
Discussion
Rationale for this study
Imaging of small animals on a clinical scanner in this
study was challenging, given the small body volume of the
rodents. The application of a dedicated small coil allowed
for acquisition of images with a high signal/noise ratio, so
that spatial resolution was adapted to small sized animals.
Another important issue was the development of a stable
logistic protocol, including optimized anaesthesia and
positioning of the animals for imaging. Sub-optimal
anaesthesia allowed the movement of the animal during
image acquisition leading to imaging artefacts. This was
especially problematic for T1-weighted images acquired
shortly after injection of the contrast medium, since this
sequence could not be repeated in the same imaging ses-
sion, due to the already injected dose. Overall, the stan-
dardization and streamlining of the logistics was an
important prerequisite for acquisition of high quality
images in this study.
Benefit of small rodent studies for improvement of HCC 
imaging techniques in human patients
Although the major aim of this study was the develop-
ment of a non-invasive imaging technique for murine
HCCs which can be used for further basic research in
mice, our results could also potentially contribute to
improvement of MR imaging of human hepatocellular
carcinoma. In the clinical situation the analysis of MR
images with respect to HCC detection mostly depends on
the experience of the radiologist as matching of MR
results with liver histology is restricted to patients with
subsequent liver resection or biopsy. In contrast, MR
imaging in mice allows the immediate comparison with
liver histology in large cohorts. Moreover, multiple
genetic and chemical mouse models are available reflect-
ing the pathogenesis of human hepatocarcinogenesis
including steatosis-, fibrosis- and cirrhosis models [21,22]
thus defining experimental mouse models as a new
attractive tool for the improvement of MR guided liver
imaging techniques.
Figure 6 Detection limits of HCC nodules in an alb-myctg mice. (A) 
In the un-enhanced T1-weighted gradient echo image of murine liver 
lesions are either not detectable or can be identified only faintly (white 
arrow). (B) Sagittal true-FISP image demonstrates slightly hyperintense 
lesion signals (green arrows). (C) In the contrast-enhanced T1 scan of 
the right hepatic lobes, multiple slightly hypointense lesions are visible 
(green arrow). These lesions cannot be clearly identified on the pre-
contrast scan (A). (D) In the T2-weighted scan hyperintense space-oc-
cupying lesions can be seen in the murine liver (green arrows). (E) Sur-
gical situs. View of two hepatic lobes in a sagittal orientation. 
Visualization of four nodules (green arrows) with 2 mm of diameter 
within non-tumorgenic liver tissue. Of note, corresponding signals 
were made visible by 3D true-FISP (compare B), T1-weighted contrast-
enhanced (compare C) and T2-weighted (compare D) MR images, but 
not in un-enhanced T1-weighted image (compare A). Labeling of ori-
entation: R: right; L: left; H: head; A: anterior; P: posterior; F: foot.
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Page 10 of 13Limitations of MRI for the detection of murine HCC
Although several studies have demonstrated that MRI
represents one of the highest imaging accuracy of all
imaging methods available to date [23], the diagnosis of
small HCC nodules in human patients by MRI is still
challenging. For human HCC >2 cm, MRI showed a
detection rate of 100%; however, the detection rate of
HCC <1 cm is only 34% [24]. In this context we demon-
strated that the monitoring of small single HCC nodules
with a diameter of 2 mm is basically feasible in mice. To
determine the limit of detection concerning tumor size, a
large number of animals with expected onset of tumor
development between 45 and 57 weeks of age were
screened by MRI and subsequent macroscopic liver anal-
ysis. These experiments demonstrated that MR imaging
in combination with our optimized parameters detects
100% of murine HCC ≥ 4 mm. However, the detection
rate of small nodules (≤ 4 mm) which is important for
determining tumor initiation was only 70%. Thus, it is
very likely, that nodules ≤ 2 mm will be only partially
detected. Nonetheless, in our study 90% of all tumors
could clearly be identified by MRI, and these findings
were confirmed by macroscopic and histopathologic
analysis.
The majority of experiments performed in this study
were carried out in c-myc transgenic animals as this is an
established and well characterized model of hepatocar-
cinogenesis. Extensive DNA-profiling analysis revealed
that this model corresponds to slow growing human
HCC associated with better survival [3,25]. However, to
Figure 7 Application of MRI in the chemical model of N-nitrosodiethylamine induced HCC in mice. Hepatocarcinogenesis was induced in WT 
mice by single application of DEN. 45 week old animals were subjected to MRI and subsequently sacrificed. (A) Macroscopic appearance of a repre-
sentative WT liver 45 weeks after DEN treatment. (B) Sagittal true-FISP imaging displays destruction of normal liver architecture; well defined, slightly 
hyperintense areas (white arrows) indicate large tumor nodules. (C) Un-enhanced T1-weighted gradient echo image of the same DEN-treated liver. 
Especially large tumors but also a sub-group of small liver lesions are detectable and appear as hypointense structures (white arrows). (D) Contrast-
enhanced T1 scans of the same liver. A sub-group of tumors (arrows) is only detectable after application of contrast agent (gadoxetic acid disodium) 
and appears highly hypointense. (E) T2-weighted scan showing strong alteration of liver anatomy due to multinodular carcinogenesis. (F-K) Histo-
pathological analysis of two representative tumor nodules. (F) Liver section of one extracted tumor (overview). One example of a nodule-in-nodule 
like structure is highlighted (white circle) and correlates with structures seen in un-enhanced T1-weighted scans showing hypointense large tumor 
and embedded hyperintense areas (lower left). (G-H) Enlarged sectional views of (F). (I-K) Histology of a second isolated tumor with moderate differ-
entiation. (I) Section overview, the corresponding appearance of the resected tumor in the MR is shown in the lower left of the figure.(J, K) Enlarged 
sectional view of (I) showing moderate pleomorphism of tumor cell nuclei and cytoplasm indicating for a moderate differentiation.
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Page 11 of 13proof that our approach to monitor murine HCC by MRI
is not restricted to c-myc dependent hepatocarcinogene-
sis, we also included a c-myc independent, non-trans-
genic HCC model in our studies by using the carcinogen
N-nitrosodiethylamine (DEN). This model usually gener-
ates multinodular HCC within 40 weeks which share a
gene expression profile of human HCC with poor prog-
nosis [3,25]. Recently, the DEN model was also used in
combination with genetic knockouts of potential tumor
promoters [26,27] to further investigate the molecular
mechanisms of HCC development.
Our own analysis revealed, that during the early phase
of DEN-mediated tumor initiation (24 weeks after DEN-
induction), MRI was not efficient in detecting small
tumor nodules in the liver (data not shown). This might
be due to the nature of these tumors with small, multi-
nodular appearance with the challenge to distinguish
between single lesions. These problems are enhanced by
the small size of the analyzed object (mice versus
humans) and a relatively low signal/noise ratio due to the
magnetic field strength of 1.5T of the used MR scanner
thus defining some limitations of clinical MR scanners in
monitoring murine HCC nodules. However, such diffi-
culties might also have been observed in larger subjects,
since the multiple small tumours have a low contrast
compared to the surrounding tissue. Nevertheless, we
clearly could detect advanced, DEN-induced liver tumors
in mice 45 weeks after tumor induction, which were ret-
rospectively characterized as well- or moderately differ-
entiated HCC, further demonstrating that clinical 1.5T
MR scanners are appropriate tools for liver cancer
research in mice.
It was shown before that it is basically possible to detect
hepatocellular carcinoma in rodents with a clinical 1.5T
MR scanner e.g. by using an orthotopic tumor cell
implantation model in rats [28]. Nevertheless, our own
study implicates significant methodical progress in com-
parison to these studies for several reasons: 1.5T MR
imaging in rats is less challenging due to their signifi-
cantly larger body volume compared to mice resulting in
a better signal/noise ratio. Moreover, mechanistical stud-
ies on hepatocarcinogenesis in rats are restricted to mod-
els of chemical tumor induction or tumor cell
transplantation as gene knockout technologies in rats are
currently not established and appropriate transgenic rat
models are limited. Although orthotopic implantation of
genetically modified HCC cells in the liver and subse-
quent MR imaging of tumor progression- or regression is
a powerful tool e.g. for drug screenings, the majority of
future animal experiments concerning HCC research will
be definitely performed in genetic modified knock out
mice targeting oncogenes or tumor suppressors. Opti-
mizing MR imaging of liver tumors in mice will further
support this approach.
Only a few studies have described the monitoring of
murine HCC by MRI so far and these studies mainly took
advantage of MR scanners specialized for small animals
with a magnetic field strength of 4.7 T or higher [29].
However, these scanners are expensive and the availabil-
ity is restricted.
Conclusion
In summary, we demonstrated that detection of murine
HCC initiation and progression in transgenic mouse
models is feasible with clinical 1.5 T MR scanners thus
allowing further analysis of potential oncogenes and
tumor suppressors in the liver by comparison of respec-
tive tumor-susceptible transgenic mouse models. Never-
theless, limitations in reliable detection and
characterization of small HCC remain an area of further
investigation. This will help to gain better insight and to
understand the underlying molecular mechanisms of
HCC initiation and development.
Materials and methods
Housing and breeding of mice
All animals used for experiments were maintained in a
temperature-controlled room with 12-hour light/dark
cycle. Animal experiments were approved by the author-
ity for environment conservation and consumer protec-
tion of the state North Rhine-Westfalia (LANUV,
Recklinghausen, Germany; reference number AZ
50.203.2-AC 5a,39/05) and the University Hospital
Aachen Animal Care Facility's guidelines. For our study
we used transgenic mice carrying a c-myc transgene
under the control of the hepatocyte-specific albumin pro-
moter (alb-myctg) of male gender as previously described
[18]. As controls, we used wildtype (WT) littermates
derived from heterozygous breeding couples.
Chemical induction of hepatocellular carcinoma in mice 
using N-nitrosodiethylamine (DEN)
For chemical induction of hepatocellular carcinoma, 14-
day old wildtype mice on a mixed C57BL6/129ola back-
ground were injected once with 25 mg/kg body weight
DEN (Sigma) intraperitoneally as described earlier
[30,31]. Usually, these mice developed multinodular HCC
between 24 - and 40 weeks of age.
Experimental protocol for MRI analysis in mice
All animal interventions including MRI analysis in mice
were carried out under anaesthesia using 100 mg/kg Ket-
amin and 10 mg/kg Rompun (i.p.). For contrast enhance-
ment 0.025 mmol/kg body weight gadoxetic acid
disodium (Gd-EOB-DTPA, Primovist®, Schering, Berlin,
Germany) was administered by tail vein injection using a
catheter with injection port (Biovalve® 22G; 1,0 × 25 mm,
Vygon, Ecouen, France).
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Achieva 1.5-Tesla Scanner MR System (Philips Medical
Systems, Best, The Netherlands). A 47 mm diameter coil
(Philips Medical Systems) was used for signal reception.
For volumetric analysis we used an off-line workstation
(View Forum, Philips Medical Systems).
Extraction and sectioning of complete livers
For preparation of whole livers, mice were anesthetized
and livers were immediately perfused through the infe-
rior vena cava with 4% formaldehyde/PBS for 20 minutes.
Subsequently the complete liver was extracted and fixed
in 4% formaldehyde/PBS for 24-48 hours and then
embedded in paraffin (Shandon Histoplast paraffin,
Thermo Scientific, Egelsbach, Germany) according to its
original three-dimensional topography. In order to per-
form tissue sections from formalin-fixed and paraffin-
embedded liver which exactly parallels MR images, the
surface of the formalin-fixed liver was marked with a
color code corresponding to topographical hallmarks (i.e.
left, right, cranial, caudal). Afterwards the whole organ
was embedded in paraffin and orientated as found in the
MR images. Serial 4 μm sections were performed and
subsequently stained with hematoxylin/eosin following
routine protocols.
Immunhistochemistry
PCNA immunhistochemistry was performed on 5 μm
paraffin embedded sections with fixation in 4% formalde-
hyde/PBS for 5 min using an anti-PCNA antibody
(Dianova, Hamburg, Germany) at a dilution of 1:200 and
a secondary goat anti-mouse-HRP antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) at a dilution of 1:100.
Final staining was performed with DAB solution (Sigma-
Aldrich, Taufkirchen, Germany) and counterstaining
with hematoxylin.
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